NAP1L1 and ovarian carcinoma: In glioma and ovarian cancers, NAP1L1, via its interaction with HDGF, activated c-Jun, an oncogenic transcription factor, to induce CCND1/CDK4/CDK6 expression resulting in cellular proliferation and chemoresistance to cisplatin (Zhu et al., 2022; Chen et al., 2021).